Advertisement

Topics

Search Results for "Hydrocodone Bitartrate 7 5 Mg"

00:34 EDT 23rd October 2017 | BioPortfolio

Matching Channels

None

Matching News

Hydromorphone HCl Injection, USP 2 mg/mL, and Levophed (Norepinephrine Bitartrate Injection, USP) 4 mg/4 mL (1 mg/mL) Vial by Hospira: Recall - Lack of Sterility Assurance

Audience: Pharmacy [Posted 09/05/2017] ISSUE: Hospira is voluntarily recalling one lot of Hydromorphone HCI Injection, USP, CII 2 mg/mL and four lots of Levophed (Norepinephrine Bitartrate Injection,...

Daiichi Sankyo to end agreement with Charleston Laboratories for hydrocodone products

Daiichi Sankyo has elected to terminate its existing agreement with Charleston Laboratories to forgo the development and commercialisation of hydrocodone products in the US for the treatment of modera...

Monitoring Opioid Use for Managing Chronic Pain

A 53-year-old woman with chronic low back pain presented for a prescription refill of hydrocodone/acetaminophen. She had partial paralysis from a thoracic spinal cord infarction secondary to aortic di...

Horizon Pharma Announces Four Poster Presentations On PROCYSBI (Cysteamine Bitartrate) Delayed-Release Capsules At

  Life Sciences Jobs   ...

Daiichi Sankyo Returns U.S. Rights for Pain Candidate to Charleston Labs

Charleston Laboratories said today it has regained U.S. rights from Daiichi Sankyo to its lead product CL-108 (hydrocodone, acetaminophen, promethazine), six months after the FDA derailed the companie...

Evofem Announces First Patient Enrolled In A Phase III Clinical Trial Of AMPHORA (L-Lactic Acid, Citric Acid, And Potassium Bitartrate) For Prevention Of Pregnancy

  Life Sciences Jobs   ...

Daiichi ends hydrocodone deal with Charleston Labs

Charleston Labs, Daiichi Sankyo end hydrocodone deal

Matching PubMed Articles

Relative Bioavailability, Intranasal Abuse Potential, and Safety of Benzhydrocodone/Acetaminophen Compared with Hydrocodone Bitartrate/Acetaminophen in Recreational Drug Abusers.

Benzhydrocodone is a hydrocodone prodrug that has been combined with acetaminophen (APAP) in a novel immediate-release analgesic. This study evaluated the relative bioavailability, intranasal abuse po...

Evaluation of the Relative Intranasal Abuse Potential of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users.

To assess the intranasal abuse potential of hydrocodone extended-release (ER) tablets developed with CIMA Abuse-Deterrence Technology compared with hydrocodone powder and hydrocodone bitartrate ER cap...

Effectiveness and Safety of Once-Daily Extended-Release Hydrocodone in Individuals Previously Receiving Immediate-Release Oxycodone for Chronic Pain.

This study evaluated the safety and effectiveness of a once-daily, single-entity, extended-release hydrocodone bitartrate (HYD) among patients with chronic noncancer and non-neuropathic pain who requi...

Impact of the Hydrocodone Schedule Change on Opioid Prescription Patterns in South Dakota.

Prescription opioid use is becoming increasingly common; consequently, opioid overdose deaths are increasing at an alarming rate. Hydrocodone, one of the most commonly abused opioids, was changed from...

The Effect of a Federal Controlled Substance Act Schedule Change on Hydrocodone Combination Products Claims in a Medicaid Population.

In 2012, hydrocodone combination products (HCPs) were the most prescribed medications in the United States. Under the Controlled Substance Act of 1970, hydrocodone alone was classified as a Schedule I...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement